Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 201–300 of 1,000
Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome
Mishima, Y., & Ishihara, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910235 · Cited by 85
Layer, P., Andresen, V., Allescher, H., Bischoff, S. C., Claßen, M., Elsenbruch, S., Freitag, M., Frieling, T., Gebhard, M., Goebel-Stengel, M., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1591-4794 · Cited by 76
Attali, T., Bouchoucha, M., & Benamouzig, R. (2013) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12098 · Cited by 78
Zeber-Lubecka, N., Kulecka, M., Ambrozkiewicz, F., Paziewska, A., Goryca, K., Karczmarski, J., Rubel, T., Wojtowicz, W., Mlynarz, P., Marczak, L., et al. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1215805 · Cited by 78
Manipulation of the Gut Microbiota as a Novel Treatment Strategy for Gastrointestinal Disorders
Foxx-Orenstein, A. E., & Chey, W. D. (2012) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2012.8 · Cited by 76
Self-citationGut Microbiota Dysbiosis in Functional Dyspepsia
Tziatzios, G., Gkolfakis, P., Papanikolaou, I. S., Mathur, R., Pimentel, M., Giamarellos‐Bourboulis, E. J., & Τriantafyllou, Κ. (2020) · Microorganisms · doi:10.3390/microorganisms8050691 · Cited by 88
“Furthermore, serotonin, apart from being responsible for normal GI transit, has been also shown to contribute to visceral hypersensitivity by affecting intestinal permeability and has been associated to methane producing IBS subjects [37].”
BackgroundInfluentialSelf-citationBest management of irritable bowel syndrome
Black, C. J., & Ford, A. C. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2019-101298 · Cited by 101
Italian guidelines for the management of irritable bowel syndrome
Barbara, G., Cremon, C., Bellini, M., Corsetti, M., Nardo, G. D., Falangone, F., Fuccio, L., Galeazzi, F., Iovino, P., Sarnelli, G., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.11.015 · Cited by 88
Sbahi, H., & Di Palma, J. A. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000087 · Cited by 75
“55 The use of the non-absorbable antibiotic rifaximin has been shown, in TARGET 1 and 2 trials, to improve non-constipated IBS symptoms, and in cases of recurrence, retreatment with rifaximin leads to incremental quality of life improvement to the enduring improvements following the initial treatment with rifaximin wh…”
BackgroundUnraveling the ties between irritable bowel syndrome and intestinal microbiota
Hong, S. N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2470 · Cited by 75
Cangemi, D. J., & Lacy, B. E. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878950 · Cited by 75
Talley, N. J., Holtmann, G., & Walker, M. M. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1076-x · Cited by 89
“The very poorly absorbed antibiotic rifaxamin has been evaluated in well-designed randomized controlled trials [119], in which patients with non-constipating IBS showed a significant improvement in both global and bloating IBS symptoms, although this antibiotic is not yet approved for use in this condition by the FDA…”
Brain‐Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders
Camilleri, M., & Lorenzo, C. D. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31823d34c3 · Cited by 82
“Its efficacy was demonstrated in 2 large randomized controlled trials (74); efficacy relative to placebo appears to persist for 8 weeks following cessation of treatment.”
BackgroundGhoshal, U. C., Nehra, A., Mathur, A., & Rai, S. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14938 · Cited by 85
Measuring response in the gastrointestinal tract in systemic sclerosis
Khanna, D., Nagaraja, V., Gladue, H. S., Chey, W. D., Pimentel, M., & Frech, T. (2013) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000434668.32150.e5 · Cited by 81
Self-citationMoshiree, B., Drossman, D. A., & Shaukat, A. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.039 · Cited by 95
Growth promotion and gut microbiota: insights from antibiotic use
Brüssow, H. (2015) · Environmental Microbiology · doi:10.1111/1462-2920.12786 · Cited by 78
Quigley, E. M. M. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.009 · Cited by 67
The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders
Losurdo, G., D’Abramo, F. S., Indellicati, G., Lillo, C., Ierardi, E., & Leo, A. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103531 · Cited by 91
“Based on such assumption, rifaximin, a non-absorbable antimicrobial agent with proved effectiveness against SIBO, has shown promising results in IBS patients without constipation, with an improvement of abdominal pain in about 40%, as reported in the TARGET trials [19].”
ResultSchmulson, M., & Chang, L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04637.x · Cited by 70
“completed phase 3 multicentre trials compared the efficacy of rifaximin at a dose of 550 mg three times daily and placebo for 14 days in patients with nonconstipating IBS.(36) Adequate relief of IBS symptom of bloating was a”
MethodInfluentialFood: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome
Chey, W. D. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.12 · Cited by 69
Self-citationSlim, M., Calandre, E. P., & Rico‐Villademoros, F. (2014) · Rheumatology International · doi:10.1007/s00296-014-3109-9 · Cited by 77
Medication Management of Irritable Bowel Syndrome
Trinkley, K. E., & Nahata, M. C. (2014) · Digestion · doi:10.1159/000362405 · Cited by 68
Rifaximin: New Therapeutic Indication and Future Directions
Rivkin, A. M., & Gim, S. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.007 · Cited by 72
Spiegel, B. M. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.030 · Cited by 67
Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature
Cohen, N. A., & Maharshak, N. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4535-9 · Cited by 70
“It is postulated that by correcting dysbiosis, it may be possible to alleviate or improve IBS symptoms, and this contention is supported by evidence of a significant clinical response to probiotics and antibiotics [31, 32].”
Bonfrate, L., Tack, J., Grattagliano, I., Cuomo, R., & Portincasa, P. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.799220 · Cited by 67
“A report of two identical randomized trials (TARGET 1 and TARGET 2) has recently shown that rifaximin, a semisynthetic, rifamycin-based non-systemic antibiotic (Figure 2), improved overall symptoms in 1260 IBS patients without constipation [134].”
BackgroundInfluentialIrritable bowel syndrome in children: Pathogenesis, diagnosis and evidence-based treatment
Sandhu, B., & Paul, S. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6013 · Cited by 80
Irritable bowel syndrome, inflammatory bowel disease and the microbiome
Major, G., & Spiller, R. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000032 · Cited by 67
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2015) · Europe PMC (PubMed Central) · Cited by 69
Zhao, J., Zheng, X., Chu, H., Zhao, J., Cong, Y., Fried, M., Fox, M., & Dai, N. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12331 · Cited by 67
Biomarkers of Irritable Bowel Syndrome
Kim, J. H., Lin, E. A., & Pimentel, M. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16135 · Cited by 77
Self-citationRobles, A., Perez Ingles, D., Myneedu, K., Deoker, A., Sarosiek, I., Zuckerman, M. J., Schmulson, M. J., & Bashashati, M. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13718 · Cited by 65
Tansel, A., & Levinthal, D. J. (2023) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000567 · Cited by 89
Cremonini, F., Nicandro, J. P., Atkinson, V., Shringarpure, R., Chuang, E., & Lembo, A. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05208.x · Cited by 64
Self-citationVisceral Pain and Gastrointestinal Microbiome
Chichlowski, M., & Rudolph, C. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15025 · Cited by 63
“91 Treatment with the antibiotic rifaximin appears to benefit some patients with IBS 92 but the population that benefits and efficacy of antibiotic treatment remains controversial.”
Furnari, M., Savarino, E. V., Bruzzone, L., Moscatelli, A., Gemignani, L., Giannini, E. G., Zentilin, P., Dulbecco, P., & Savarino (2012) · PubMed · Cited by 70
Pharmacologic Agents for Chronic Diarrhea
Lee, K. J. (2015) · Intestinal Research · doi:10.5217/ir.2015.13.4.306 · Cited by 73
González‐Castro, A. M., Martínez, C., Salvo‐Romero, E., Fortea, M., Pardo‐Camacho, C., Pérez‐Berezo, T., Alonso‐Cotoner, C., Santos, J., & Vicario, M. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13417 · Cited by 63
“Furthermore, antibiotic trials with both neomycin and rifaximin show improvement in global symptoms, also suggesting a relationship between microbiota and IBS[59,60].”
BackgroundPost-Infectious Irritable Bowel Syndrome
Lee, Y. Y., Chandramouli, A., & Rao, S. S. C. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0595-4 · Cited by 70
Qi, L.-Y., Yang, J., Yan, S., Tu, J., She, Y.-F., Li, Y., Chi, L.-L., Wu, B., & Liu, C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.48817 · Cited by 75
Chen, M., Tang, T. ‐., Wang, Y., Shui, J., Xiao, X. ‐., Lan, X., Yu, P., Zhang, C., Wang, S. ‐., Yao, J., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14817 · Cited by 61
“Rifaximin showed similar changes in response rates when compared with placebo.(10,11,13) However, this assumption needs further study to confirm.”
ResultFunctions of intestinal microflora in children
Buccigrossi, V., Nicastro, E., & Guarino, A. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a3500 · Cited by 61
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
Airola, C., Severino, A., Porcari, S., Fusco, W. G., Mullish, B. H., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023) · Antibiotics · doi:10.3390/antibiotics12050868 · Cited by 82
Is It Diverticular Disease or Is It Irritable Bowel Syndrome?
Spiller, R. E. (2012) · Digestive Diseases · doi:10.1159/000335721 · Cited by 72
Gut microbiota in health and disease
Icaza-Chávez, M. E. (2013) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2014.02.009 · Cited by 86
“001.(77) The studies that show the existence of a gut-brainmicrobiota axis are surprising.”
BackgroundMiazga, A., Osiński, M., Cichy, W., & Żaba, R. W. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.09.001 · Cited by 64
Meyrat, P., Safroneeva, E., & Schoepfer, A. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12087 · Cited by 59
“published phase III, double-blind, placebo-controlled TARGET trials.(17) In these trials, IBS patients without constipation were assigned either to a group that received rifaximin (at a dose of 550 mg) or to a group that received placebo three times daily for 2 weeks.”
MethodResultDiagnosis and treatment of diarrhea-predominant irritable bowel syndrome
Lacy, B. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s93698 · Cited by 58
“4%).(76) Data suggest that 1 patient would experience an AE with rifaximin for every 846 patients who would benefit (number needed to harm =8,971 and number needed to treat =10.”
Agents that act luminally to treat diarrhoea and constipation
Menees, S. B., Saad, R. J., & Chey, W. D. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.162 · Cited by 61
Self-citationUse of rifaximin in gastrointestinal and liver diseases
Shayto, R. H., Mrad, R. A., & Sharara, A. I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6638 · Cited by 65
Sinagra, E., Morreale, G. C., Mohammadian, G., Fusco, G., Guarnotta, V., Tomasello, G., Cappello, F., Rossi, F., Amvrosiadis, G., & Raimondo, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6593 · Cited by 80
Chey, W. D., Shah, E. D., & DuPont, H. L. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819897531 · Cited by 62
Self-citationDiagnosis and management of IBS in adults.
Wilkins, T., Pepitone, C., Alex, B. K., & Schade, R. R. (2012) · PubMed · Cited by 72
It's a gut feeling: How the gut microbiota affects the state of mind
Farmer, A. D., Randall, H. A., & Aziz, Q. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2013.270389 · Cited by 57
“Pimentel et al. (2011) have reported the combined results of two phase III trials evaluating the utility of the non-absorbable antibiotic rifaximin in non-constipated IBS, demonstrating a small but significant improvement of global symptoms, bloating, abdominal pain, and loose or watery stools.”
BackgroundBreath tests and irritable bowel syndrome
Rana, S. V., & Malik, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7587 · Cited by 64
Ringel-Kulka, T., Benson, A. K., Carroll, I. M., Kim, J., Legge, R. M., & Ringel, Y. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00044.2015 · Cited by 53
Self-citationGhaffari, P., Shoaie, S., & Nielsen, L. K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03365-z · Cited by 63
“Several facts support this tendency: some pre-/probiotics can relieve IBS symptoms [58]; visceral colonic hypersensitivity that is a critical feature of the IBS can be transferred to germfree mice by fecal transplantation [59]; randomized controlled trails with rifaximin, a no-absorbable antibiotic, revealed benefit f…”
BackgroundGarofalo, C., Cristiani, C. M., Ilari, S., Passacatini, L. C., Malafoglia, V., Viglietto, G., Maiuolo, J., Oppedisano, F., Palma, E., Tomino, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061701 · Cited by 79
Kashyap, P., Moayyedi, P., Quigley, E. M. M., Simrén, M., & Vanner, S. J. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14817 · Cited by 73
“Rigorous studies show a therapeutic gain of ~ 10% over placebo, 32 a response that is similar or less than other therapies targeting neural rather than microbial signaling pathways.”
BackgroundGhoshal, U. C., Srivastava, D., & Misra, A. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0901-6 · Cited by 56
Brenner, D. M., & Sayuk, G. S. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01116-z · Cited by 55
Role of the duodenal microbiota in functional dyspepsia
Brown, G., Hoedt, E. C., Keely, S., Shah, A., Walker, M. M., Holtmann, G., & Talley, N. J. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14372 · Cited by 62
Pistiki, A. C., Galani, I., Pyleris, E., Barbatzas, C., Pimentel, M., & Giamarellos‐Bourboulis, E. J. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.008 · Cited by 60
Self-citationEluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
Lacy, B. E., Chey, W. D., Cash, B. D., Lembo, A. J., Dove, L. S., & Covington, P. S. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.72 · Cited by 54
Self-citationGuidelines on the management of irritable bowel syndrome
Pietrzak, A., Skrzydło-Radomańska, B., Mulak, A., Lipiński, M., Małecka-Panas, E., Reguła, J., & Rydzewska, G. (2018) · Gastroenterology Review · doi:10.5114/pg.2018.78343 · Cited by 23
Irritable bowel syndrome: a concise review of current treatment concepts
Wall, G. C., Bryant, G. A., Bottenberg, M. M., Maki, E. D., & Miesner, A. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8796 · Cited by 56
Mars, R. A. T., Frith, M., & Kashyap, P. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.058 · Cited by 54
Stein, S. L. (2013) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2013.08.005 · Cited by 62
Association between Brachyspira and irritable bowel syndrome with diarrhoea
Jabbar, K. S., Dolan, B., Eklund, L., Wising, C., Ermund, A., Johansson, Å., Törnblom, H., Simrén, M., & Hansson, G. C. (2020) · Gut · doi:10.1136/gutjnl-2020-321466 · Cited by 62
“2 31 In our investigation, three in four patients with spirochetosis experienced partial, but sustained, symptom relief following metronidazole treatment.”
Jin, Y. T., Ren, X., Li, G., Li, Y., Zhang, L., Wang, H., Qian, W., & Hou, X. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13841 · Cited by 58
Downs, I. A., Aroniadis, O. C., Kelly, L., & Brandt, L. J. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000924 · Cited by 61
Marteau, P., Guyonnet, D., Lafaye de Micheaux, P., & Gelu, S. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12078 · Cited by 50
Roland, B. C., Ciarleglio, M. M., Clarke, J. O., Semler, J. R., Tomakin, E., Mullin, G. E., & Pasricha, P. J. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3166-7 · Cited by 55
Treatment of abdominal pain in irritable bowel syndrome
Vanuytsel, T., Tack, J. F., & Boeckxstaens, G. E. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0966-7 · Cited by 59
“Indication and efficacy of retreatment is unclear 11 [90]”
BackgroundGiamarellos-Bourboulis, E. J., Pyleris, E., Barbatzas, C., Pistiki, A., & Pimentel, M. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0484-6 · Cited by 51
Self-citationPimentel, M., Cash, B. D., Lembo, A., Wolf, R. A., Israel, R. J., & Schoenfeld, P. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4598-7 · Cited by 51
Self-citationIrritable Bowel Syndrome: Modern Concepts and Management Options
Sayuk, G. S., & Gyawali, C. P. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.036 · Cited by 61
“needed-to-treat around 11),(108, 109) the effect persisting beyond the duration of use.”
BackgroundBloating and functional gastro-intestinal disorders: Where are we and where are we going?
Iovino, P., Bucci, C., Tremolaterra, F., Santonicola, A., & Chiarioni, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14407 · Cited by 58
Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome
Camilleri, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.794223 · Cited by 50
“Benefit was also documented for 10 weeks after cessation of treatment [46].”
BackgroundLi, Y., Hong, G., Yang, M. J., Li, G., Jin, Y. T., Xiong, H., Qian, W., & Hou, X. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104936 · Cited by 54
Pharmacotherapy for Irritable Bowel Syndrome
Camilleri, M., & Ford, A. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110101 · Cited by 46
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome
Stern, E., & Brenner, D. M. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2018.2 · Cited by 56
“003 for all outcomes).(70) Rifaximin was well tolerated”
BackgroundMethodInfluentialThe Pharmacology of Visceral Pain
Johnson, A. C., & Meerveld, B. G. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2015.11.002 · Cited by 56
Leventogiannis, K., Gkolfakis, P., Spithakis, G., Tsatali, A., Pistiki, A. C., Sioulas, A. D., Giamarellos‐Bourboulis, E. J., & Τriantafyllou, Κ. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9401-3 · Cited by 50
“The response rate of the placebo arm in the two TARGET studies did not exceed 32% [22].”
BackgroundBloating and Abdominal Distension: Clinical Approach and Management
Mari, A., Baker, F. A., Mahamid, M., Amara, H., Carter, D., Boltin, D., & Dickman, R. M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00924-7 · Cited by 57
Small Intestinal Bacterial Overgrowth
Bushyhead, D. W., & Quigley, E. M. M. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.02.008 · Cited by 54
Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
“Journal of Neurogastroenterology and Motility while in 2 large RCTs, the patients took rifaximin 550 mg tid for 2 weeks.(94,95) Four RCTs with dichotomous endpoints support the efficacy of rifaximin in patients with IBS-D and those with relapsing symptoms of IBS-D, and repeat rifaximin treatment was efficacious and we…”
BackgroundNew strategies for the management of diverticular disease: insights for the clinician
Boynton, W., & Floch, M. H. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478679 · Cited by 48
“It has been shown that rifaximin could be useful in irritable bowel syndrome and small bowel bacterial overgrowth by reducing bloating, abdominal pain, flatulence and loose stools [Sharara et al. 2006; Pimentel et al. 2011].”
BackgroundCaecal pH is a biomarker of excessive colonic fermentation
Farmer, A. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i17.5000 · Cited by 47
Lucak, S., Chang, L., Halpert, A., & Harris, L. A. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16663396 · Cited by 47
Choi, C. H., Kwon, J. G., Kim, S. K., Myung, S. ‐., Park, K. S., Sohn, C. ‐., Rhee, P. ‐., Lee, K. J., Lee, O. Y., Jung, H. ‐., et al. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12544 · Cited by 46
Camilleri, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.261 · Cited by 47
Irritable bowel syndrome: new and emerging treatments
Halland, M., & Saito, Y. A. (2015) · BMJ · doi:10.1136/bmj.h1622 · Cited by 53
Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
Colomier, E., Algera, J. P., & Melchior, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629026 · Cited by 60
“On the contrary, all trials suggest that rifaximin effectively relieves bloating in IBS-D patients (Pimentel et al., 2011; Lembo et al., 2016b).”
ResultAntibiotics for the treatment of irritable bowel syndrome.
Basseri, R. J., Weitsman, S. R., Barlow, G. M., & Pimentel, M. (2011) · Europe PMC (PubMed Central) · Cited by 63
Self-citationOh, J. H., Jang, Y. S., Kang, D., Chang, D. K., & Min, Y. W. (2019) · Nutrients · doi:10.3390/nu11122887 · Cited by 45
“Treating IBS is important because the symptoms cause impairment in health-related quality of life, leading to increased use of health resources and reduced work productivity [2].”
BackgroundSmall intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
Aziz, I., Törnblom, H., & Simrén, M. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000348 · Cited by 45
Chang, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2499 · Cited by 56
Foxx–Orenstein, A. E. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16633050 · Cited by 48
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.